A Phase II Randomized Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence
Brief description of study
This is a double-blind placebo-controlled clinical trial (n = 200) of varenicline for the treatment of cocaine dependence that utilizes contingency management to promote treatment attendance. Participants will be randomized (1:1) to receive varenicline (1.0 mg BID) for 12 weeks. Primary outcome measures include biochemically verified cocaine and nicotine use.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Addictive Behavior, Cocaine-Related Disorders, cocaine
-
Age: Between 18 Years - 65 Years
-
Gender: All
Updated on
27 Aug 2018.
Study ID: 814643